Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

Area of Science:

• Immunology
• Endocrinology
• Pediatrics

Background:

• Type 1 diabetes involves autoimmune destruction of pancreatic beta cells.
• Golimumab, a TNF-α inhibitor, is approved for other autoimmune conditions.
• Its efficacy in preserving beta-cell function in newly diagnosed type 1 diabetes in youth is unknown.

Purpose of the Study:

• To evaluate the effect of golimumab on preserving beta-cell function in children and young adults with newly diagnosed type 1 diabetes.
• To assess endogenous insulin production and exogenous insulin requirements.

Main Methods:

• Phase 2, multicenter, placebo-controlled, double-blind trial.
• 84 participants (6-21 years) with new-onset type 1 diabetes received golimumab or placebo for 52 weeks.
• Primary endpoint: 4-hour C-peptide AUC post-mixed meal tolerance test.

Main Results:

• Golimumab group showed significantly higher 4-hour C-peptide AUC (0.64 vs 0.42 pmol/mL, P<0.001) at 52 weeks.
• Lower insulin use and higher partial-remission response (43% vs 7%) in the golimumab group.
• No significant difference in glycated hemoglobin; increased investigator-reported hypoglycemia in the golimumab group.

Conclusions:

• Golimumab improved endogenous insulin production in youth with new-onset type 1 diabetes.
• Golimumab treatment led to reduced exogenous insulin use compared to placebo.
• Further research may explore golimumab's role in managing type 1 diabetes.